How Compounding Pharmacies Source GLP-1 API: The Supply Chain Explained

Every compounded GLP-1 vial starts with a raw ingredient: the active pharmaceutical ingredient, or API. Before a pharmacist draws it into solution, before a technician fills it into a sterile vial, before a courier ships it in a cold pack — someone manufactured the peptide, someone imported it, and someone verified it was actually what the label claimed. That supply chain is where quality is either built or broken.

Most patients never think about where their medication's active ingredient came from. For brand-name drugs, that's reasonable — Novo Nordisk and Eli Lilly control their manufacturing end-to-end. For compounded medications, the supply chain involves more handoffs, and each one is a point where quality controls either hold or fail. Here's how the system actually works.

Step 1: Peptide Synthesis

Semaglutide and tirzepatide are synthetic peptides — chains of amino acids assembled through solid-phase peptide synthesis (SPPS) or recombinant DNA technology. The manufacturers of GLP-1 API are chemical companies, not pharmacies. They operate large-scale synthesis facilities, often in the United States, India, or China, and produce pharmaceutical-grade peptide powder in bulk.

The quality of the synthesis determines everything downstream. A well-run facility produces peptide with high purity (typically above 95% by HPLC testing), low impurity levels, and consistent batch-to-batch characteristics. A poorly run facility produces peptide that might technically be semaglutide but contains elevated levels of deletion sequences, truncation products, or racemized amino acids — impurities that can affect both safety and efficacy.

FDA Registration Requirements

Under the Drug Supply Chain Security Act (DSCSA) and FDA regulations, facilities that manufacture API for use in compounding must be registered with the FDA as drug establishments. This registration requires the facility to list its products, comply with current Good Manufacturing Practice (cGMP) standards, and be subject to FDA inspection.

Registration does not guarantee quality — it establishes a regulatory floor. An FDA-registered facility that has never been inspected is technically compliant but unverified. Pharmacies that go beyond the minimum will request documentation of recent inspections, audit results, and detailed certificates of analysis for each API lot they purchase.

Step 2: Distribution and Import

API manufacturers typically sell to pharmaceutical distributors, who then supply compounding pharmacies. For domestically manufactured API, the distribution chain is relatively short. For imported API — which represents a significant portion of the U.S. supply — additional regulatory requirements apply.

Imported API must clear FDA customs review, and the importer must maintain documentation showing the manufacturer's FDA registration, the product's Drug Master File (if applicable), and lot-specific certificates of analysis. The FDA can and does block shipments of API that lack proper documentation or come from unregistered facilities.

Step 3: Pharmacy Receipt and Verification

When a compounding pharmacy receives a shipment of GLP-1 API, it should not simply shelve it and start compounding. Quality-focused pharmacies implement incoming material testing protocols that include:

• Identity verification: Confirming the material is actually semaglutide (or tirzepatide), not a substituted or mislabeled compound. This is typically done through infrared spectroscopy, mass spectrometry, or comparison HPLC testing.
• Potency verification: Checking that the peptide content matches the supplier's certificate of analysis. Discrepancies here could mean the pharmacy is compounding with material that is either more or less potent than expected.
• Sterility and endotoxin testing: For API that will be used in injectable preparations, verifying that the raw material does not carry bacterial contamination or pyrogenic endotoxins.
• Certificate of analysis review: Comparing the supplier's CoA against the pharmacy's internal specifications for purity, impurities, moisture content, and related substances.

Step 4: Compounding and Finished Product Testing

Once verified API enters the pharmacy's cleanroom, it's compounded into the final dosage form — typically a sterile injectable solution in a multi-dose vial. The compounding process itself introduces additional quality variables: was the API weighed accurately? Was the solution prepared under proper sterile conditions? Was the final product tested for potency, sterility, and endotoxin levels before release?

USP Chapter <797> (for sterile preparations) and Chapter <795> (for non-sterile preparations) set the standards that pharmacies must follow during this process. PCAB-accredited pharmacies undergo additional third-party auditing to verify compliance with these standards.

The Gray Market Problem

Outside the regulated supply chain, a parallel market exists for GLP-1 peptides sold as "research chemicals" or "for research use only." These products are not manufactured under cGMP, are not sourced from FDA-registered facilities, and are not subject to the testing requirements that apply to pharmaceutical API. They are not legal for human use, regardless of how they are marketed.

The distinction matters because some online sellers blur the line between research peptides and pharmacy-grade API. If a "pharmacy" is sourcing its semaglutide from research chemical suppliers rather than FDA-registered API manufacturers, the entire quality framework described above collapses.

How to Verify the Supply Chain

Patients cannot audit a pharmacy's supply chain directly, but they can ask targeted questions:

• "Is your GLP-1 API sourced exclusively from FDA-registered manufacturers?"
• "Can you provide a certificate of analysis for the API lot used in my prescription?"
• "Does your pharmacy conduct independent identity and potency testing on incoming API?"
• "What accreditations does your compounding pharmacy hold?" (Look for PCAB or ACHC)

A pharmacy that can answer all four questions clearly — and provide documentation — is operating within the regulated supply chain. One that deflects, refuses, or cannot produce these records may not be.

Providers With Transparent Pharmacy Partnerships

What This Means for You

The quality of a compounded GLP-1 is only as good as the weakest link in its supply chain. A pharmacy that sources API from FDA-registered manufacturers, tests incoming materials independently, compounds under USP-compliant conditions, and tests finished products before release is doing everything the regulatory framework intends. A pharmacy that cuts corners at any step is transferring that risk to you.